TCT-580 Initial, Prospective Analysis of Uncontrolled Hypertensive Patients Included in the Global Paradise System (GPS) Registry Outside of the United States
No Thumbnail Available
Authors
Brouwers S.
Fengler K.
GenthZotz S.
Azizi M.
Sharp A.
Saxena M.
Persu A.
Daemen J.
Pathak A.
McClure C.
Check for full-text access
Issue Date
2025
Type
Article
Language
Keywords
Alternative Title
Abstract
Background: The Global Paradise System (GPS) Registry is a real world, all comers, retrospective, and prospective registry being conducted in 9 countries outside of the United States. GPS was designed to assess the long-term safety and effectiveness of ultrasound renal denervation (uRDN) with the Paradise System when used according to its labelling. Method(s): Office blood pressure (BP) measurements were collected from all patients with a subset of patients also collecting home and ambulatory BP. This is the first prospective analysis of the GPS Registry data. Result(s): At the time of analysis, a total of 448 patients were included in the GPS Registry, of which 396 had been treated. Of these, 317 patients, (80%) were prospectively enrolled and 212 met the criteria for uncontrolled hypertension defined as a baseline office systolic (SBP) >= 140 mmHg. Of the 212 uncontrolled hypertensive patients, 137 completed 3 months follow-up and 92 completed 6 months follow-up. The median number of anti-hypertensive medications at baseline for the prospective uncontrolled cohort was 3.0 [0.0, 10.0]. Average age was 57.1 +/- 12.6 yrs, 46% of patients were female and the majority were white, where data was available. Significant co-morbidities included diabetes (25.6%), hyperlipidemia (71.4%), coronary artery disease (31.6%), heart failure (21.4%), and history of hypertensive crisis (24.5%). Mean baseline office BP was 172.4 +/- 23.1/ 99.2 +/- 16.1 mmHg (n=212) which was reduced to 156.5 +/- 25.7/ 91.6 +/- 17.5 (-15.5/-6.6 mmHg, n=137) at 3 months follow-up and further reduced to 150.8 +/- 25.3/ 87.6 +/- 15.1 (-18.4/-9.8 mmHg, n=92) at 6 months follow-up. On average, the number of anti-hypertensive medications remained unchanged over 6 months follow-up. Few adverse events were reported, mainly related to access site complications. Conclusion(s): In summary, early prospective data from the real-world GPS Registry in patients with uncontrolled hypertension, show a substantial blood pressure lowering effect of uRDN at 3- and 6-months follow-up without any safety concerns. Categories: ENDOVASCULAR: Hypertension Therapies and Renal Denervation Copyright © 2025
Description
Citation
Publisher
License
Journal
Journal of the American College of Cardiology
Volume
Issue
Transcatheter Cardiovascular Therapeutics Abstracts.